Option Agreement Sample Contracts

CatchMark Timber Trust, Inc. – THIRD AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Third Amendment to Option Agreement (“Third Amendment”) is made and entered into effective as of August 21, 2018 (the “Effective Date”), by and between LRT III LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – FIRST AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This First Amendment to Option Agreement (“First Amendment”) is made and entered into effective as of June 28, 2018 (the “Effective Date”), by and between LRT IV LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – SECOND AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Second Amendment to Option Agreement (“Second Amendment”) is made and entered into effective as of August 3, 2018 (the “Effective Date”), by and between LRT III LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – FIRST AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This First Amendment to Option Agreement (“First Amendment”) is made and entered into effective as of June 28, 2018 (the “Effective Date”), by and between FIA TIMBER PARTNERS II, L.P., a Delaware limited partnership (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – SECOND AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Second Amendment to Option Agreement (“Second Amendment”) is made and entered into effective as of August 3, 2018 (the “Effective Date”), by and between LRT IV LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – FIRST AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This First Amendment to Option Agreement (“First Amendment”) is made and entered into effective as of June 28, 2018 (the “Effective Date”), by and between LRT III LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – THIRD AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Third Amendment to Option Agreement (“Third Amendment”) is made and entered into effective as of August 21, 2018 (the “Effective Date”), by and between FIA TIMBER PARTNERS II, L.P., a Delaware limited partnership (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – THIRD AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Third Amendment to Option Agreement (“Third Amendment”) is made and entered into effective as of August 21, 2018 (the “Effective Date”), by and between LRT IV LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CatchMark Timber Trust, Inc. – SECOND AMENDMENT TO OPTION AGREEMENT (March 1st, 2019)

This Second Amendment to Option Agreement (“Second Amendment”) is made and entered into effective as of August 3, 2018 (the “Effective Date”), by and between FIA TIMBER PARTNERS II, L.P., a Delaware limited partnership (hereinafter referred to as “Seller”), and CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).

CVS HEALTH Corp – PARTNERSHIP EQUITY PROGRAM Participant Purchased RSUs, Company Matching RSUs and Company Matching Option Agreement (February 28th, 2019)

AGREEMENT, by and between CVS Health Corporation, a Delaware corporation (the “Company”), and ______________ (“Participant”), effective on ___________, herein after known as the “Grant Date” (this “Agreement”).

Airxpanders Inc – OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) (February 28th, 2019)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, AirXpanders, Inc. (the “Company”) has granted you an option to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”).

Jufeel International Group – EXCLUSIVE EQUITY OPTION AGREEMENT (February 21st, 2019)

This Exclusive Equity Option Agreement (this “Agreement”) is entered into as of July 27, 2017 in Kaifeng, People’s Republic of China (“PRC”) by and among the following persons:

Quidel Corp /De/ – Notice of Grant of Nonqualified Stock Options and Option Agreement (February 15th, 2019)

Effective ______________, you have been granted a Nonqualified Stock Option to buy ________ shares of Common Stock of Quidel Corporation (the “Company”) at $_____ per share, pursuant to Section 6.1 of the Quidel Corporation 2018 Equity Incentive Plan (the “Plan”).

Regeneron Pharmaceuticals Inc – Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement for Time-Based Vesting Tarrytown, New York 10591 Option Awards [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] (February 7th, 2019)

Effective <date> (the “Grant Date”) you have been granted a Non-Qualified Option to buy [    ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) stock at $[    ] per share.

Regeneron Pharmaceuticals Inc – Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement for Time-Based Vesting Tarrytown, New York 10591 Option Awards [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] (February 7th, 2019)

Effective <date> (the “Grant Date”) you have been granted a Non-Qualified Option to buy [    ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) stock at $[    ] per share.

Regeneron Pharmaceuticals Inc – Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement Tarrytown, New York 10591 [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] (February 7th, 2019)

Effective <date> (the “Grant Date”) you have been granted a Non-Qualified Option to buy [    ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) stock at $[    ] per share.

Lexaria Bioscience Corp. – WARRANT AND OPTION AGREEMENT (January 22nd, 2019)

This Warrant and Option Agreement (“Agreement”) is executed as of January 15, 2019, by Lexaria Nicotine LLC, a Delaware limited liability company (the “Company”) and Lexaria Bioscience Corp., a Nevada corporation (“Company Holdings”), in favor of Altria Ventures Inc., a Virginia corporation (the “Initial Holder”), in accordance with the terms and subject to the conditions set forth in this Agreement. The Company, Company Holdings and the Initial Holder are each referred to herein as a “Party” and collectively as the “Parties.”

Positive Physicians Holdings,inc. – OPTION AGREEMENT (January 22nd, 2019)

This OPTION AGREEMENT (this “Agreement”) is entered into as of [●], 201__, among Insurance Capital Group, LLC, a Delaware limited liability company (“ICG”), ________________,1 a ________________ (“___” and, together with ICG, the “Positive Shareholders”), Diversus, Inc., a Delaware corporation (“Diversus”), and Positive Physicians Holdings, Inc., a Pennsylvania corporation (“Positive”).

Long Blockchain Corp. – Second Amended and Restated Loan and Option Agreement (January 22nd, 2019)

Court Cavendish Ltd, a company incorporated in England and Wales under no. 04290684, having its registered address at The Care House, Randalls Way, Leatherhead, Surrey, KT22 7TW (the “Lender”).

United World Holding Group Ltd. – Equity Option Agreement (January 18th, 2019)

This Equity Option Agreement (this “Agreement”) is executed by and among the following Parties as of December 5, 2018 in Beijing, the People’s Republic of China (“China” or the “PRC”):

Alector, Inc. – SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. CO- DEVELOPMENT AND OPTION AGREEMENT between ALECTOR, INC. and ABBVIE BIOTECHNOLOGY, LTD. Dated as of October 16, 2017 (January 7th, 2019)

This Co-Development and Option Agreement (this “Agreement”) is made and entered into effective as of October 16, 2017 (the “Execution Date”) by and between Alector, Inc. (f/k/a Alector LLC), a Delaware corporation (“Licensor”), and AbbVie Biotechnology, Ltd., a Bermuda limited company (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Stealth BioTherapeutics Corp – STEALTH BIOTHERAPEUTICS CORP Nonstatutory Option Agreement (December 28th, 2018)
Geron Corp – Geron Corporation 2018 Inducement Award Plan Option Agreement (Nonstatutory Stock Option) (December 14th, 2018)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Geron Corporation (the “Company”) has granted you an option under its 2018 Inducement Award Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

Immune Pharmaceuticals Inc – Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights (November 28th, 2018)

FORT LEE, NJ and NEW YORK, NY (November 27, 2018) – Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, and Vector Therapeutics, Inc. (“Vector”), a biopharmaceutical company acquiring, developing and commercializing oncology therapeutics, today announced the execution of an agreement that gives Vector an option to acquire worldwide rights to Ceplene.

Ideanomics, Inc. – SHARE PURCHASE AND OPTION AGREEMENT (November 14th, 2018)

This SHARE PURCHASE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), dated July 16, 2018, is entered into by and between Seven Stars Cloud Group, Inc., a corporation incorporated under the laws of Nevada (the “Company”), and Star Thrive Group Limited , a company incorporated and existing under the laws of the British Virgin Islands (the “Purchaser”).

Synthorx, Inc. – RESEARCH FUNDING AND OPTION AGREEMENT (November 13th, 2018)

This Agreement is entered into this 31st day of July, 2014 (the “Effective Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 (“TSRI”), and Synthorx, Inc., a Delaware corporation, located at 11099 North Torrey Pines Road, La Jolla, California 92037 (“Sponsor”), with respect to the facts set forth below.

Surface Oncology, Inc. – FIRST AMENDED AND RESTATED DEVELOPMENT AND OPTION AGREEMENT (November 13th, 2018)

This First Amended and Restated Development and Option Agreement (this “Agreement”) made effective as of October 3, 2018 (the “Amended Effective Date”), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA  02141 (“Surface”).

Tat Technologies Ltd – OPTION AGREEMENT (November 13th, 2018)

The Company duly adopted approved the 2012 Stock Option Plan, as amended, a copy of which is attached as Exhibit A hereto, forming an integral part hereof (the “Plan”); and

Tat Technologies Ltd – OPTION AGREEMENT Made as of _____, __, _____ (November 13th, 2018)
DiaMedica Therapeutics Inc. – OPTION AGREEMENT This Agreement dated as of the day of , 20xx, (November 9th, 2018)

WHEREAS the Participant is a bona fide senior officer, director, Employee, or Consultant of the Corporation or any subsidiary of the Corporation;

DiaMedica Therapeutics Inc. – OPTION AGREEMENT This Agreement dated as of the ● day of ●, ●, BETWEEN: DIAMEDICA THERAPEUTICS INC. a corporation incorporated under the laws of Canada, (hereinafter called the “Corporation”), OF THE FIRST PART, - and - of the • of ●, in the ● of ●, (hereinafter called the “Participant”), OF THE SECOND PART. (November 9th, 2018)

WHEREAS the Participant is a bona fide Senior Officer, Director, Employee, Management Company Employee or Consultant of the Corporation or any subsidiary of the Corporation;

CLS Holdings USA, Inc. – OPTION AGREEMENT (November 6th, 2018)

This OPTION AGREEMENT (this “Agreement”), is entered into as of October 31, 2018 (the “Effective Date”), among CLS Massachusetts, Inc., a Massachusetts corporation (“Optionee”), CLS Holdings USA, Inc., a Nevada corporation (“CLS Holdings”), and In Good Health, Inc., a Massachusetts not-for-profit corporation (the “Company”). Company, CLS Holdings and Optionee are referred to herein individually as a “Party” and collectively as the “Parties.”

OvaScience, Inc. – MILLENDO THERAPEUTICS SAS FIRST AMENDMENT TO SHAREHOLDERS AND OPTION AGREEMENT (November 6th, 2018)

This First Amendment to the Shareholders and Option Agreement (the “Amendment”), dated as of September 28, 2018 is by and between MILLENDO THERAPEUTICS, INC., a Delaware corporation(together with its successors or assigns that hold Shares, the “Majority Shareholder”), and OTONNALE SAS, a French société par actions simplifiée, whose registered office is located at 15  Chemin du Saquin, Espace Europen, Bät G, 69130 Ecully, France, registered under number 539 195 438 with the Lyon Trade and Companies Register (together with its successors or assigns that hold Shares, the “Minority Shareholder”), in the presence of MILLENDO THERAPEUTICS SAS (formerly known as ALIZÉ PHARMA SAS), a French société par actions simplifiée with a share capital of EUR 220,950, whose registered office is located at Espace européen - 15, Chemin du Saquin, 69130 Ecully, registered at the Lyon Trade and Companies register under number 497 575 621 (the “Company”). Each of the Majority Shareholder and the Minority Shar

OvaScience, Inc. – SHAREHOLDERS AND OPTION AGREEMENT OF ALIZÉ PHARMA SAS December 19, 2017 (November 6th, 2018)

This SHAREHOLDERS AND OPTION AGREEMENT (the “Agreement”), dated as of December 19, 2017 is by and between MILLENDO THERAPEUTICS, INC., a Delaware corporation(together with its successors or assigns that hold Shares, the “Majority Shareholder”), and OTONNALE SAS, a French société par actions simplifiée, whose registered office is located at 15 Chemin du Saquin, Espace Europen, Bät G, 69130 Ecully, France, registered under number 539 195 438 with the Lyon Trade and Companies Register (together with its successors or assigns that hold Shares, the “Minority Shareholder”), in the presence of ALIZÉ PHARMA, a French société par actions simplifiée, whose registered office is located at 15, Chemin du Saquin, Espace Européen, 69130 Ecully, France, registered under number 497 575 621 with the Lyon Trade and Companies Register (the “Company”).  Each of the Majority Shareholder and the Minority Shareholder are sometimes referred to herein as a “Shareholder” and, collectively, as the “Shareholders”.

CatchMark Timber Trust, Inc. – OPTION AGREEMENT (November 1st, 2018)

THIS OPTION AGREEMENT (this “Agreement”), made as of the Effective Date (as defined in paragraph 26 below), by and among LRT III LLC, a Delaware limited liability company (hereinafter referred to as “Seller”), CATCHMARK TIMBER TRUST, INC., a Maryland corporation (hereinafter referred to as “Purchaser”).